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Abstract: Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by 
noncaseating granulomatous inﬁ  ltration of virtually any organ system. Treatment is often under-
taken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies 
have suggested a prominent role for tumor necrosis factor-alpha (TNF-α) in the inﬂ  ammatory 
process seen in sarcoidosis. TNF-α and interleukin-1 are released by alveolar macrophages in 
patients with active lung disease. Corticosteroids have proved to be efﬁ  cacious in the treatment of 
sarcoidosis, possibly by suppressing the production of TNF-α and other cytokines. Three agents 
are currently available as speciﬁ  c TNF antagonists: etanercept, inﬂ  iximab, and adalimumab. 
Although data from noncomparative trials suggest that all three have comparable therapeutic 
effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are 
less consistent. In this review, current data on the effectiveness are summarized.
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Introduction
Sarcoidosis is a systemic granulomatous disorder of indeterminate origin, manifested 
by the presence of noncaseating granulomas of virtually any organ system. Although 
precise epidemiological studies have not been undertaken, there are several reasons 
why we might infer that an infective agent or agents might be the trigger(s), including 
spatial, seasonal, and occupational clustering (Bowman et al 2003).
There are two aspects of the granulomatous response of sarcoidosis: the initial 
event, leading to granuloma formation, and the evolution of the response as either 
resolution or chronic disease. In studies of patients with an acute form of the disease, a 
high proportion of CD4-positive lymphocytes have been identiﬁ  ed in bronchoalveolar 
lavage (BAL) ﬂ  uid (Pinkston et al 1983). These T cells are activated, as shown by their 
increase of interleukin-2 (IL-2) receptors and the spontaneous release of IL-2 by these 
cells. IL-18 has also been reported as possibly playing a central part in sarcoid granu-
loma formation (Shigehara et al 2001). This activation is associated with macrophage 
activation, interferon production, and formation of the granuloma, and has been cited 
as an example of the Th-1 response (Baumer et al 1997). In more than 60% of sar-
coidosis patients, the granulomatous response resolves during the following 2–5 years. 
The events leading to resolution include an inﬂ  ux of CD-8 positive lymphocytes. The 
maintenance of the granuloma may be through the IL-12, and resolution is associated 
with the cytokine IL-10, which suppresses the inﬂ  ammatory response (Moller et al 
1996). The cytokines associated with chronic disease include IL-8, IL-12, and tumor 
necrosis factor-alpha (TNF-α) (Ziegenhagen et al 1997).
TNF-α and sarcoidosis
TNF-α is a 17.5-kd protein that plays a signiﬁ  cant role in antigen-stimulated, cell-
mediated immune responses and in the development of noncaseating granulomas in Therapeutics and Clinical Risk Management 2008:4(6) 1306
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a variety of diseases (Tracey 1994; Chensue et al 1995). In 
sarcoidosis, alveolar macrophage-derived TNF-α participates 
in the induction and maintenance of granulomas (Kunkel 
et al 1989). High levels of TNF-α and high levels of TNF-α 
released from alveolar macrophages seem to correlate with 
disease progression (Marques et al 1999). In light of its 
inhibitory activity against TNF-α, pentoxifylline has been 
proposed as a therapeutic agent for sarcoidosis and patients 
exhibited a favorable response, so other pure and potent TNF-
α antagonists, such as the new biological anti-TNF-α, would 
be an alternative for the treatment of sarcoidosis.
The TNF-α inhibitors have distinct efﬁ  cacy proﬁ  les. 
Whereas all 3 available agents (etanercept, inﬂ  iximab, and 
adalimumab) have demonstrated efﬁ  cacy in the treatment of 
RA, efﬁ  cacy in other inﬂ  ammatory arthritides and granulo-
matous diseases such as Crohn’s disease, Wegener’s granu-
lomatosis and sarcoidosis varies (Haraoui 2005a, 2005b). 
There are no trials comparing efﬁ  cacy among different 
anti-TNF-α in sarcoidosis.
Multiple reasons for this discrepancy have been theorized. 
They all target the same molecule, but in a different way. 
Inﬂ  iximab is a humanized mouse monoclonal antibody, adali-
mumab a fully human monoclonal antibody and etanercept 
a construct comprising two human p75 TNF-α receptors 
coupled to the Fc portion of a monoclonal human antibody. 
Etanercept, adalimumab and inﬂ  iximab have different bind-
ing characteristics, with inﬂ  iximab and adalilumab binding 
to both soluble and membrane-bound TNF and etanercept 
binding primarily to soluble TNF (Scallon et al 2002). These 
differences in binding may manifest as differing effects on 
complement activation and apoptosis. Inﬂ  iximab and adali-
mumab may lyse in vitro TNF-producing cells via activation 
of complement (Reinold 2003) and also appears to induce 
apoptosis of immune/inﬂ  ammatory cells (Lügering et al 
2001). Other differences in the efﬁ  cacy proﬁ  les of these 
drugs are likely related to the pathophysiology of the diseases 
(eg, role of lymphotoxin) as well as drug characteristics (eg, 
dosing, pharmacokinetics, or immunogenicity).
Clinical use and adverse effects
There are no clinical trials comparing efﬁ  cacy among differ-
ent TNF inhibitors in patients with sarcoidosis. The choice of 
agent therefore depends on other factors, including patients’ 
convenience, access to treatment, and patients’ preferences. 
Inﬂ  iximab requires infusion intravenously every four to eight 
weeks, performed by a health care professional. The usual 
dose is 3 mg/kg body weight; some patients require higher 
doses. Etanercept and adalimumab are self-administered by 
subcutaneous injection. Etanercept is given at a dose of 25 mg 
twice weekly or 50 mg weekly, and adalimumab is given at 
a dose of 40 mg every 2 weeks.
Common minor adverse events include injection site 
reactions with etanercept and adalimumab and infusion reac-
tions with inﬂ  iximab. Rare serious adverse events include 
optic neuritis, exacerbations of previously quiescent multiple 
sclerosis, aplastic anemia, and interstitial lung disease; lupus-
like syndromes and hepatotoxicity may also occur. Serious 
infections are a particular concern, especially respiratory and 
skin infections (Scott and Kingsley 2006). TNF inhibitors 
should be stopped in the presence of serious infections. Sus-
ceptibility to intracellular pathogens may be increased, and 
primary tuberculosis and reactivation of prior tuberculosis are 
speciﬁ  c problems; and, as a rule, patients should be screened 
for tuberculosis before the initiation of therapy. The overall 
risk of cancer is controversial (Scott and Kingsley 2006). 
The only systematic review, which focused on randomized, 
controlled trials involving inﬂ  iximab and adalimumab, but 
not etanercept, reported a dose-related increased risk of 
cancer (Pettersen et al 2002). In contrast, national registries 
have not yet found an increase in solid cancers after treat-
ment with TNF inhibitors. An increase in lymphomas has 
been reported with all TNF inhibitors. However, because 
there is a preexisting association of lymphomas with severe 
RA and systemic inﬂ  ammation, the exact contribution of 
therapy with TNF inhibitors is difﬁ  cult to dissect. Given 
these uncertainties, it seems sensible to use extreme caution 
when considering the use of TNF inhibitors in many patients 
with a history of malignant disease, or even to avoid them 
altogether, and to warn patients that the risk of cancer with 
this form of therapy remains unknown. Since inﬂ  iximab 
increases mortality when used to treat severe heart failure 
in patients without arthritis, TNF inhibitors should be used 
cautiously, if at all, when mild heart failure is present, and 
are best avoided when heart failure is severe. Nonetheless, 
there is no evidence that TNF inhibitors increase the risk of 
new-onset cardiac failure in patients with RA. Patients are 
usually advised not to conceive while taking TNF inhibitors 
and to avoid these treatments during pregnancy or lactation. 
To date, no actual adverse events have been described in 
those pregnancies that have occurred in patients taking TNF 
inhibitors. Table 1 summarizes the dose, route of administra-
tion, and most prevalent adverse effects.
Because the experience with anti-TNF in patients with 
sarcoidosis is still limited, multicenter trials are needed to 
validate the safety and efﬁ  cacy in these patients. Currently, 
there is insufﬁ  cient data to support anti-TNF as ﬁ  rst-line Therapeutics and Clinical Risk Management 2008:4(6) 1307
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therapy for sarcoidosis or neurosarcoidosis, but is deﬁ  nitely 
an option in refractory cases. The optimal dose, duration 
of therapy, and long term toxicity of anti-TNF in patients 
with refractory sarcoidosis are yet to be determined in 
prospective trials.
Treatment with anti-TNF 
in different manifestations 
of sarcoidosis
To present the scientiﬁ  c evidence of anti-TNF-α treatment in 
patients with sarcoidosis we have made a division according 
to the organ affected.
Cutaneous sarcoidosis
Cutaneous sarcoidosis occurs in up to one third of patients 
with systemic sarcoidosis. Recognition of cutaneous lesions 
is important because they provide a visible clue to the diagno-
sis, and are an easily accessible source of tissue for histologic 
examination. Because lesions can exhibit many different 
morphologies, cutaneous sarcoidosis is known as one of the 
“great imitators” in dermatology. Speciﬁ  c manifestations 
include papules, plaques, lupus pernio, scar sarcoidosis, and 
rare morphologies such as alopecia, ulcers, hypopigmented 
patches, and ichthyosis (Katta 2002).
Treatment of cutaneous lesions can be frustrating. For 
patients with severe lesions or widespread involvement, 
the most effective treatment is systemic glucocorticoids. 
Other medications may be used in refractory cases, includ-
ing such agents as hydroxychloroquine, methotrexate, and 
thalidomide.
A growing number of publisher reports suggest that 
anti-TNF-α therapies may be effective in the treatment of 
numerous inﬂ  ammatory skin diseases including sarcoidosis 
(Alexis and Strober 2006). The majority of these reports 
are in the form of individual case reports and small case 
series. Tuchinda and Wong (2006) reported a patient with 
chronic progressive cutaneous sarcoidosis, unsuccessfully 
treated with systemic steroid and immunosuppressive agents, 
who responded signiﬁ  cantly to etanercept as monotherapy. 
Khanna and colleagues (2003) described a patient with lupus 
pernio, resistant to corticosteroids and disease modifying 
antirheumatic agents, who responded to the addition of 
etanercept.
Doty and associates (2005) reported their experience 
with inﬂ  iximab in ten patients with sarcoidosis, ﬁ  ve with 
disﬁ  guring lupus pernio lesions; the response was dramatic. 
Heffernan and Anadkat (2005) reported a case of recalcitrant 
cutaneous sarcoidosis with multiple and disseminated vio-
laceous papules and plaques which achieved 90% clearance 
by week 6 with intravenous inﬂ  iximab therapy. Roberts 
and colleagues (2003) described a woman with systemic 
sarcoidosis with cutaneous manifestations in form of a mass 
in a right eyelid that resolved between the third and fourth 
dose of inﬂ  iximab. Haley and associates (2004) reported a 
patient with severe mutilating cutaneous sarcoidosis (lupus 
pernio), who showed partial response to courses of a wide 
spectrum of immunomodulators and cytotoxic therapies who 
developed signiﬁ  cant side effects due to prolonged high-
dose corticosteroids, and responded rapidly to inﬂ  iximab. 
Pritchard and Nadarajah (2004) reported ﬁ  ve patients, one 
with sarcoid skin nodules that disappeared after 2 days of inf-
liximab infusions. Sweiss and colleagues (2005) described 9 
patients, three with cutaneous manifestations (one with mass 
lesions of the lip and nose, one with extensive psoriasiform 
rash and one with extremely painful bilateral lower extremity 
ulcerative sarcoidosis requiring high-dose narcotics for pain 
control), without response to corticosteroids and methotrex-
ate and mycophenolate mofetil that resolved with inﬂ  iximab. 
Another individual case has been described with response to 
inﬂ  iximab (Baughman and Lower 2001; Mallbris et al 2003; 
Meyerle and Schorr 2003).
Finally, there are 2 cases of cutaneous sarcoidosis 
responding to adalimumab, one with ulcer on lower extremity 
that persisted despite of treatment with prednisone, hydroxy-
chloroquine and methotrexate and resolved nine weeks after 
the initiation of adalimumab (Philips et al 2005) and other 
one with reddish-purple nodules on the face and shins and 
numerosus hyperpigmented patches and erosions on the legs 
(Heffernan and Smith 2006).
Table 1 Principal characteristics of anti-TNF drugs
Drug  Dose  Route of administration  Adverse effects (common for all anti-TNF)
Inﬂ  iximab  3–5 mg/kg  Infusion intravenously every four to eight weeks  Local erythema Increased risk of infections
Etanercept  25 mg  Subcutaneous injection, twice weekly  Increased risk of tuberculosis reactivation
Etanercept  50 mg  Subcutaneous injection, weekly  Congestive heart failure Desmyelinating diseases
Adalimumab  40 mg  Subcutaneous injection every two weeks  Neoplasm
Abbreviation: TNF, tumor necrosis factor.Therapeutics and Clinical Risk Management 2008:4(6) 1308
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Patients with cutaneous sarcoidosis who are refractory to 
corticosteroids and/or steroid-sparing agents, or those who 
develop signiﬁ  cant drug toxicity, may be candidates for 
treatment with TNF inhibitors. The optimal dose, duration of 
therapy, and long-term toxicity of anti-TNF in patients with 
refractory cutaneous sarcoidosis are yet to be determined in 
prospective trials.
Neurosarcoidosis
Central and peripheral nervous system involvement 
is estimated to be 5%, but other studies have reported 
a prevalence of 15%–16%. The clinical course may be 
acute, subacute or chronic with insidious onset (Lower et al 
1997; Marangoni et al 2006). A growing number of papers, 
specially reports in form of individual case reports, suggest 
that anti-TNF-α therapies may be effective in the treatment 
of neurosarcoidosis.
Carter and colleagues (2004) presented a 41-year-old 
woman who presented with headaches, fatigue, diffuse myal-
gias and arthralgias, galactorrhea, and short term memory 
problems; an elevated serum prolactin level was detected. 
A magnetic resonance image (MRI) of the brain showed 
an enlarged pituitary gland and transphenoidal resection 
revealed multiple noncaseating granulomas. Prednisone 
and methotrexate was administered. Two months later, the 
patient developed left homonymous superior quadrant hemi-
anopsia. A repeat MRI of the brain showed multiple areas 
of prominent enhancement, including the suprasellar and 
parasellar region, intracranial prechiasmal optic nerves and 
optic chiasm, intracranial ﬁ  fth nerve bilaterally, cavernous 
sinus, and infundibulum. After a total of ﬁ  ve treatments of 
intravenous cyclophosphamide, while on prednisone 10 mg 
daily, the patient developed acute bilateral vision loss caused 
by recurrence of her optic neuropathy. She was started on 
intravenous inﬂ  iximab 5 mg/kg at 0, 2, 6 weeks, and then 
every 8 weeks. After 5 months, and a total of ﬁ  ve treatments 
of inﬂ  iximab, the patient symptomatically improved, with 
decreased headaches and arthralgias and no new visual 
symptoms or worsening of her visual acuity.
Solberger and colleagues (2004) reported a patient with 
a biopsy-proven progressive neurosarcoidosis involving the 
hypophysis, the right vestibulocochlear nerve, the spinal 
cord, and the peripheral nervous system, refractory to cortico-
steroids and azathioprine, in whom inﬂ  iximab was associated 
with a markedly improved clinical outcome.
Pettersen and colleagues (2002) described a man who 
developed biopsy-proven sarcoidosis 16 years previously, 
initially involving the skin (lupus pernio), and subsequently 
the liver (granulomatous hepatitis), knees (synovitis), lungs 
(hilar lymphadenopathy), and brain (left temporal lobe lesion 
with associated focal seizures). His neurosarcoidosis was 
complicated by an episode of prolonged status epilepticus. 
Despite undergoing radiation therapy to the left temporal 
lobe and receiving full courses of prednisone, azathioprine, 
methotrexate, hydroxychloroquine, chloroquine, and cyclo-
sporine, he experienced progressive neurologic involve-
ment with confusion, disorientation, aggressive behavior, 
and right hemiparesis, dysmetria, dysdiadochokinesis and 
truncal ataxia. MRI revealed multiple supratentorial granu-
lomas, including a large, left medial temporal lobe lesion 
with associated vasogenic edema. Despite receiving regular 
rehabilitation therapy and medications to control seizures and 
aggressive behavior, he remained confused and disoriented. 
Inﬂ  iximab was administered IV at a dose of 5 mg/kg and 
was repeated at 2 and 6 weeks. Within 1 week of receiving 
the ﬁ  rst dose of inﬂ  iximab, the patient experienced a marked 
reduction in agitation. At 6 weeks, his right hemiparesis and 
hyperreﬂ  exia resolved and his right facial weakness, right 
appendicular ataxia, and truncal ataxia improved. Repeat 
MRI revealed reduced volume of all lesions and almost 
complete resolution of surrounding edema.
Doty and colleagues (2005) reported their experience 
with inﬂ  iximab in ten patients with sarcoidosis, one with 
neurosarcoidosis with headache, seizures and paresthesias 
in whom MRI demonstrated parenchymal and meningeal 
enhancement in frontal lobe region. Inﬂ  iximab was associ-
ated to prednisone and 3 months later the clinical symptoms 
showed improvement.
Katz and colleagues (2003) presented 2 patients with 
optic disc swelling secondary to neurosarcoidosis; one of 
them requiring treatment with inﬂ  iximab: a woman with 
headache, chronic visual loss, papilledema, and optic atro-
phy characteristic of chronic intracranial hypertension. MRI 
showed bifrontal cerebral edema with a plaque frontal pachy-
meningeal enhancement. Her visual loss progressed despite 
conventional therapies, and maintained with inﬂ  iximab.
On the other hand, Guilpain and colleagues (2004) 
reported a patient with optic bilateral neuropathy secondary 
to granulomatous inﬁ  ltration of nerve optic, where therapy 
combining prednisone, methotrexate and inﬂ  iximab was 
started without signiﬁ  cant improvement of visual acuity.
Finally, Pritchard and Nadarahaj (2004) described a 
report of ﬁ  ve patients, one with a myelopathy secondary to 
neurosarcoidosis, with a pronounced response to treatment 
with inﬂ  iximab.There is no case with neurosarcoidosis and 
etanercept or adalimumab.Therapeutics and Clinical Risk Management 2008:4(6) 1309
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Currently, there is insufﬁ  cient data to support inﬂ  iximab 
as ﬁ  rst-line therapy for neurosarcoidosis, but it does hold 
promise as a potential second-line therapy. It deﬁ  nitely is an 
option in refractory cases. The combination of inﬂ  iximab and 
methotrexate is recommended if this therapeutic strategy is 
employed for neurosarcoidosis.
Ocular sarcoidosis
Ocular disease is a common feature of sarcoidosis (Jabs 
and Johns 1986; Usi et al 2002). The manifestations include 
anterior, intermediate, and posterior uveitis. The interme-
diate and/or posterior uveitis is often chronic and can be 
associated with a loss of vision (Dana et al 1996). In addition 
to the inﬂ  ammation, lumpy or ﬂ  at glial membrane, known 
as snowbanking, over the pars plana of the ciliary body 
transforms intermediate uveitis into pars planitis. The pars 
plana has been used as a speciﬁ  c landmark for inﬂ  ammation. 
Inﬂ  ammation in that area is associated with chronic disease 
and represents a difﬁ  cult management issue for the ophthal-
mologist. Sarcoidosis is one of the more important causes 
of pars planitis. The treatment for uveitis includes therapy 
with corticosteroids, used topically, periocularly, and/or 
systemically (Krystolik et al 1998). However, the long term 
local and systemic use of corticosteroids is often associated 
with side effects, including cataracts and glaucoma. Because 
of these complications, alternatives to steroid therapy are 
often sought for the treatment of chronic uveitis. Among 
the immunosuppressive drugs, methotrexate has been com-
monly used (Dev et al 1999; Samson et al 2001). Although 
methotrexate is useful in many patients, incomplete control 
of the uveitis can sometimes occur. In these cases treatment 
with anti-TNF-α may be an option.
Baughman and colleagues (2005) studied the effective-
ness of etanercept in the treatment of patients with ocular sar-
coidosis who have persistent disease despite treatment with 
methotrexate for at least 6 months. Patients were randomized 
to receive either etanercept, 25 mg, or an equal volume of 
physiologic saline solution subcutaneously twice a week for 
6 months. All patients were maintained with methotrexate 
therapy throughout the study. The primary end point of the 
study was the change of the ophthalmologist examination 
after 6 months of therapy. Anterior uveitis was present in 
16 patients, posterior uveitis in 5 and pars planitis in 9. 
Etanercept was well tolerated. However, it was not associated 
with a marked improvement in this group of patients with 
chronic ocular sarcoidosis.
There are various reports about treatment of sarcoid-
osis with inﬂ  iximab. Saurenmann and colleagues (2006) 
described the efﬁ  cacy of anti-TNF-α (etanercept 11 patients 
and inﬂ  iximab 13 patients) in children with persistently active 
uveitis despite treatment with at least 1 standard immuno-
suppressive drug. One patient had sarcoidosis and received 
inﬂ  iximab. Inﬂ  iximab resulted in better clinical responses 
with less ocular complications than etanercept.
Benitez del Castillo and colleagues (2005a) evaluated 
the long term efﬁ  cacy and safety of inﬂ  iximab as treatment 
for noninfectious posterior uveitis in 7 patients (5 diagnosed 
with Behçet´s disease, 1 with chronic idiopathic multifocal 
choroiditis and one diagnosed with sarcoidosis). Three intra-
venous doses of 5 mg/kg of inﬂ  iximab was administered at 
weeks 0, 2 and 6, and was repeated in patients undergoing a 
relapse of uveitis after initial remission. Improvement was 
deﬁ  ned as amelioration of visual acuity or disappearance of 
retinal exudates and/or vitreous opacities. All patients were 
followed up for at least 36 months and at the end all eyes 
had improved in term of signs of inﬂ  ammation.
Baughman and colleagues (2005b) reported their expe-
rience with inﬂ  iximab in chronic ocular inﬂ  ammation in 
14 patients with various underlying ocular conditions includ-
ing 7 patients with sarcoidosis. All patients had persistent 
inﬂ  ammation despite systemic immunosuppressive agents 
and all but 1 experienced marked improvement. Four patients 
who had previously received etanercept with either no 
response or subsequent relapse responded to inﬂ  iximab.
Lindstedt and colleagues (2005) described the effect of 
additional treatment with anti-TNF-α therapy in a case series 
of 13 patients with serious sight threatening uveitis (6 with 
Behçet’s disease, one with sarcoidosis). Inﬂ  iximab treatment 
resulted in an effective suppression of ocular inﬂ  amma-
tion in all patients. In patients with non-Behçet’s disease 
uveitis visual acuity in 6 out of 8 improved or was stable. 
Pritchard and Nadarajah (2004) report 5 patients, 2 with 
chronic granulomatous uveitis and 1 with several organs 
affected by sarcoidosis including uveitis, who showed rapid 
improvement after the infusion.
For ocular sarcoidosis refractory to conventional treat-
ment, inﬂ  iximab must be considered as second-line treat-
ment; with the actual evidence indicating nﬂ  iximab resulted 
in better clinical responses with less ocular complications 
than etanercept.
Pulmonary sarcoidosis
The lungs are affected in more than 90% of patients, usually 
presenting as interstitial disease. Symptoms are dry cough, 
dyspnea, and chest discomfort. Pulmonary sarcoidosis has 
an unpredictable course that may result in spontaneous Therapeutics and Clinical Risk Management 2008:4(6) 1310
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remission or lead to progressive loss of lung function with 
ﬁ  brosis. There are four stages of pulmonary sarcoidosis. 
Patients with stage I or II disease may have no symptoms, 
whereas stages III and IV can be characterized by progressive 
dyspnea, loss of lung function, and ﬁ  brosis. Airway involve-
ment can occur and may result in airﬂ  ow limitation, persistent 
cough and, in severe cases, bronchiectasis. Spontaneous 
remission can be expected in 55%–90% of patients with 
stage I disease, 40%–70% with stage II disease, 10%–20% 
with stage III disease, and 0% to 5% with stage IV disease 
(Baughman 2004; Wu and Schiff 2004).
Corticosteroids are the mainstay of treatment for sarcoid-
osis. Alternative drugs are required in chronic resistant sar-
coidosis and/or in conditions where systemic corticosteroids 
are contraindicated. Immunosuppressive agents (chlorambu-
cil, cyclophosphamide, methotrexate, cyclosporine, azathio-
prine), anticytokine agents (thalidomide, pentoxifylline), and 
antimalarials (chloroquine, hydroxychloroquine) have been 
used in such situations. Chlorambucil and cyclophosphamide 
have been used in anecdotal cases of pulmonary sarcoidosis 
as corticosteroid-sparing agents. Therapy with anti-TNF-α 
may be an option in these situations (Fazzi 2003).
Ulbricht and colleagues (2003) described a patient with 
severe sarcoidosis involving the lung and liver. Various 
treatment regimens with azathioprine, methotrexate, cyclo-
phosphamide, and pentoxifylline failed to control the disease 
and therapy with inﬂ  iximab was commenced. Arthritis, pul-
monary and liver involvement improved, and they were able 
to taper the corticosteroid treatment to a lower-dose regimen 
with no need for additional immunosuppressive treatment.
Pritchard and Nadarajah (2004) reported ﬁ  ve patients, 
including a woman with pulmonary sarcoidosis with dys-
pnoea, arthralgias and fatigue.This patient was receiving 
prednisone 40 mg daily and methotrexate 7.5 mg weekly 
when infliximab was started. Dyspnoea and arthralgia 
improved 1–2 months after treatment. A computed tomog-
raphy (CT) scan of the thorax before and after 6 months 
of treatment with inﬂ  iximab showed improvement in the 
enlarged hilar lymph nodes.
Roberts and associates (2003) presented a case of multi-
system sarcoidosis that was refractory to treatment with mul-
tiple immunosuppressive agents. Treatment with inﬂ  iximab, 
as part of combination therapy, was added. At the time that 
inﬂ  iximab therapy was started, patient’s lung function was 
stable on a regimen of systemic steroids and azathioprine 
and its addition provided no further beneﬁ  t.
Sweiss and colleagues (2005) described 9 patients, 
4 of them with systemic and pulmonary affectation that 
were treated with inﬂ  iximab. All cases showed partial or 
complete resolution of adenopathy, and shortness of breath 
improved.
A prospective, open-label, phase-2 treatment trial with 
etanercept in pulmonary sarcoidosis has been published 
recently (Utz et al 2003). Study hypotheses included the 
following: (1) patients treated with etanercept will clinically 
improve or remain stable, obviating the need for corticoste-
roid treatment; and (2) patients responding to etanercept will 
exhibit higher pretreatment lung TNF-α expression as well 
as the suppression of lung TNF-α expression during treat-
ment compared to nonresponders. Fourteen patients demon-
strated stage II, and 3 demonstrated stage III disease. Five of 
17 patients were treatment successes, while another patient 
withdrew from the study after 3 months. Eleven patients did 
not respond to therapy. The fact that patients did not respond 
to therapy was secondary to the deterioration seen both in 
radiographs and in the results of pulmonary function tests. 
Serum TNF-α was present at low but measurable levels 
at baseline. Interestingly, enzyme-linked immunosorbent 
assay measurements at 6 months demonstrated signiﬁ  cant 
increases in total serum level of TNF-α. No consistent dif-
ferences were observed in either TNF-α level or bioactivity 
comparing those patients whose conditions had improved or 
those in whom the disease had progressed while receiving 
etanercept.
Another phase 2, multicenter, randomized, double-blind, 
placebo-controlled study has been conducted in 138 patients 
with chronic pulmonary sarcoidosis (Baughman et al 2006). 
Eligible adult patients had histologically proven sarcoidosis, 
diagnosed at least 1 year prior to screening, evidence of 
parenchymal disease on chest radiograph and a forced vital 
capacity (FVC) 50%–85% of the predicted value. Patients 
must have been treated with at least 10 mg/day of prednisone 
or equivalent or one or more immunosuppressants for at 
least 3 months prior to screening. Patients were randomized 
to receive intravenous infusions of inﬂ  iximab or placebo at 
weeks 0, 2, 6, 12, 18, 24, and followed through week 52. The 
primary endpoint was the change from baseline to week 24 
in percent of predicted FVC. Inﬂ  iximab therapy resulted in a 
statistically signiﬁ  cant improvement in percent of predicted 
FVC at week 24 Finally, we recently described a patient with 
pulmonary and pleural sarcoidosis resistant to treatment with 
prednisone and methotrexate who resolved with adalimumab 
(Callejas-Rubio et al 2005).
In patients with progressive stage II or III pulmonary 
sarcoidosis, there are a preponderance of treatment failures 
using etanercept as a single agent. It is not clear whether there Therapeutics and Clinical Risk Management 2008:4(6) 1311
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exists a small subset of patients with pulmonary sarcoidosis 
who respond to therapy with etanercept alone. In patients 
with refractory or recurrent pulmonary sarcoidosis, inﬂ  ix-
imab and probably adalimumab must be considered as an 
alternative treatment.
Renal sarcoidosis
The kidneys may be involved in sarcoidosis in various 
ways. Because the granuloma epithelioid cells may produce 
calcitriol, sarcoid patients commonly have hypercalciuria, 
nephrocalcinosis, and stone disease and may develop 
hypercalcemia. The renal interstitium may be involved with 
granuloma formation. An association with renal neoplasms, 
notably papillary carcinomas, has been described. The glom-
eruli may be involved in sarcoidosis and IgA nephropathy, 
membranous IgG deposits, or even extracapillary crescent 
formation may occur (Gobel et al 2001). Although cortico-
steroids are effective in advanced tubulo-interstitial nephri-
tis due to sarcoidosis, long term treatment is necessary to 
preserve renal function and to delay the onset of end-stage 
renal disease (Rajakariar et al 2006). Steroid-dependant or 
refractory cases may respond to other immunosuppressants 
including anti-TNF-α agents.
There are two case reports of treatment with inﬂ  ix-
imab in renal sarcoidosis. Thumfart and colleagues (2005) 
described the case of a boy presenting with severe arterial 
hypertension and acute renal failure caused by an isolated 
sarcoid granulomatous interstitial nephritis. Renal function 
improved initially with prednisone treatment but later, the 
patient showed signs of severe steroid toxicity and progres-
sive renal failure. Monthly treatment with inﬂ  iximab was 
started, resulting in steady improvement in renal function and 
resolution of renal granulomata. In addition, antihypertensive 
medication could be reduced.
Ahmed and associates (2007) present a patient with acute 
renal failure due to isolated granulomatous inﬁ  ltration of 
the renal parenchyma. Renal biopsy showed granulomatous 
interstitial nephritis with noncaseating granulomas. There was 
no evidence of extrarenal sarcoid involvement. Prednisone of 
60 mg daily resulted in signiﬁ  cant improvement in renal func-
tion. Because of recurrent ﬂ  ares on steroid taper and steroid 
toxicity, treatment with inﬂ  iximab was instituted and resulted 
in stabilization of renal function. Steroid-dependant or refrac-
tory renal sarcoidosis cases may respond to inﬂ  iximab.
Other manifestations
Fouchier and colleagues (2004) reported a patient with 
persistent, refractory symptomatic pulmonary sarcoidosis, 
complicated by a congenital muscular disease: McArdle’s 
disease (a glycogen storage disease caused by myophos-
phorylase deﬁ  ciency). As the desaturations during mild 
exercise caused by the sarcoidosis aggravated the negative 
consequences of his muscle disease and he failed to respond 
adequately to corticosteroids and methotrexate, the patient 
was treated experimentally with inﬂ  iximab. The results 
were favorable: after 17, 21, and 36 months there was an 
improvement in various lung function parameters, and his 
fatigue was reduced.
Menon and associates (2004) reported a patient treated 
with interferon-α who developed hypercalcemia and renal 
insufﬁ  ciency as presenting clinical manifestation of sarcoid-
osis. Prednisone therapy was effective in controlling hyper-
calcemia but had to be discontinued due to an increase in 
hepatitis C viral RNA count. Inﬂ  iximab was used as therapy. 
The patient received three doses of inﬂ  iximab (5 mg/kg) and 
achieved a rapid decline in serum calcium to normal levels 
in 7 days; the serum calcium level has remained normal 
3 months after the last infusion.
Yee and Pochapinet (2001) described a woman with sar-
coidosis presenting with severe protein-losing enteropathy, 
hypoalbuminemia, and proximal myopathy who had not 
responded adequately to corticosteroid therapy and whose 
clinical course was further complicated by acute tubular 
necrosis and renal failure requiring long term hemodialysis. 
Enteropathic and myopathic symptoms resolved after inﬂ  ix-
imab therapy, and the serum albumin level also improved.
Mandel and colleagues (2005) describe a case report of a 
patient with sarcoidosis with parotid gland swellings who did 
not respond to standard therapy. Despite the use of various 
immunosuppressive agents, the swellings failed to resolve 
over a three-year period. The patient’s condition was treated 
successfully with inﬂ  iximab. Finally, Hobbs (2005) presented 
the ﬁ  rst documented evidence that intraarticular injection of 
etanercept is clinically beneﬁ  cial and well tolerated in the 
setting of sarcoid arthritis.
Table 2 summarizes the studies of anti-TNF-α on 
different manifestations of sarcoidosis.
Table 2 Summary of studies of effects of anti-TNF on sarcoidosis
Clinical manifestation  Anti-TNF considered
Cutaneous sarcoidosis  Inﬂ  iximab and adalimumab
Neurosarcoidosis Inﬂ  iximab
Ocular sarcoidosis  Inﬂ  iximab
Pulmonary sarcoidosis  Inﬂ  iximab and adalimumab
Renal sarcoidosis  Inﬂ  iximab
Abbreviation: TNF, tumor necrosis factor.Therapeutics and Clinical Risk Management 2008:4(6) 1312
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Conclusions
Corticosteroids are the mainstay of treatment for sarcoidosis. 
Neverthless, alternative drugs, such as anti-TNF-α may be 
required in chronic resistant sarcoidosis and/or in conditions 
where systemic corticosteroids are contraindicated.
Three agents are currently available as speciﬁ  c TNF-
α antagonists: etanercept, inﬂ  iximab and adalimumab. 
Although date from noncomparative trials suggest that all 
3 have comparable therapeutic in rheumatoid arthritis, their 
effects in granulomatous diseases as sarcoidosis probably 
are more variable. Most of the information available comes 
from isolated clinics cases or series of cases, and as these 
type of papers usually suffers from the publication bias, 
the results must be taken with precaution. Inﬂ  iximab, and 
probably adalimumab, appears to be more effective in the 
treatment of different manifestation of refractory sarcoid-
osis, and would probably be the anti TNF of election in 
these patients.
Additional studies are needed to better deﬁ  ne these differ-
ences and optimize the clinical utilization of these agents.
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